Raltegravir (isentress) is an antiretroviral medicine currently used to treat HIV. It works by stopping the virus from replicating.

Research found that Human Endogenous Retrovirus (HERV), a family of viruses in the human genome similar to retrovirus, can be a cause or trigger for multiple sclerosis (MS). Because HERV are involved in certain cancers and autoimmune diseases including multiple sclerosis (MS), Raltegravir was tested as a potential RRMS treatment.

The study INSPIRE (NCT01767701) aimed to determine if isentress is effective in preventing the progression of RRMS. The participants took raltegravir for three months and underwent monthly MRI scans. By the end of the study, raltegravir failed to prove any benefit — it not reduce MS inflammation.

There is no information currently available concerning raltegravir’s future role in MS treatment.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187282/
  2. https://www.mssociety.org.uk/ms-research/treatments-in-the-pipeline/raltegravir